Navigation Links
RA Drugs Not Implicated In Cancer

Rheumatoid arthritis (RA) patients have an increased risk of developing lymphoma and leukemia. The autoimmune, inflammatory disease that causes a lot of joint pain does have the risk of cancer. //Researchers speculate that antirheumatic drugs (DMARDs) – including tumor necrosis factor alpha (TNFá) antagonists, a type of biologic DMARD may play a role in this.

TNF blockers, which work by attaching to and impeding chemical messengers behind inflammation, have had a significant impact on the treatment of RA. They have also been linked to lymphoma among users. In fact, reports of lymphoma prompted the Food and Drug Administration to mandate adding a cancer risk warning to the labels of three TNF blockers: etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira).

Motivated by persistent concerns and inconclusive studies, researchers at Harvard Medical School's Brigham and Women's Hospital set out to investigate the association between treatment with TNF blockers and occurrence of cancer in a large sample of patients with RA. Their results, featured in the September 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/
journal/arthritis), indicate that biologic DMARD therapy poses no greater risk for cancer than therapy with a standard prescription DMARD, methotrexate (MTX).

The researchers focused on 7,830 RA patients, age 65 and older, drawn from healthcare databases in New Jersey, Pennsylvania, and British Columbia, Canada. Subjects included 1,152 biologic DMARD users and 7,306 MTX users. Of those treated with a biologic DMARD, 64 percent had used etanercept, 33 percent had used infliximab, and the remaining 2 percent had used anakinra (Kineret). 55 percent had previously used MTX and 39 percent were receiving MTX when they began anti-TFN therapy.

Based on medical utilization information, the researchers measured every subject's general health and RA-related characteristics during the 6-mo nth period before exposure to either a biologic DMARD or MTX. In general, biologic DMARD users had more severe RA than MTX users. No subject had a diagnosis of any cancer before starting their prescribed drug treatment. Each subject was followed after beginning use of either a biologic DMARD or MTX, with attention to diagnosis of cancer followed by any course or combination of palliative care, biopsy, radiation, chemotherapy, or surgery. Using time-varying propensity scores to adjust for a wide range of possible factors and stratified proportional hazards regression, researchers estimated the effects of biological DMARDs on cancer.

From their rigorous definition of cancer, researchers identified a total of 11 cancers of the blood and lymphatic systems and 46 cancerous tumors during 2,940 person-years of biologic DMARD use, and 58 cancers of the blood and lymphatic systems and 558 tumors during 30,300 person-years of MTX use. Comparing biologic DMARD users with MTX users, the hazard ratio was 1.37 for blood-related cancers and 0.91 for solid tumors. The overall difference in estimated cancer risk was less than 5 percent between RA patients treated with a TNF blocker and those treated with a standard DMARD.

"We found no significant increase in the risk of cancers in biologic DMARD users," notes the study's lead authors, Soko Setoguchi, M.D. Dr.P.H and Sebastian Schneeweiss, M.D, Sc.D. "Our data indicate that it is unlikely that RA patients who have received biologic agents have a much greater risk of lymphoproliterative disorders, hematologic malignancies, and solid tumors compared with MTX users." Drs, Setoguchi and Schneeweiss, however, acknowledges the challenge of studying the effects of a relatively novel therapy on rare forms of blood cancer, as well as the need for ongoing studies into the risks and benefits associated with anti-TNF therapy.

Source: Eurekalert

Source-Eurekalert
RA
'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... The American ... for the scientific development, healthcare training and clinical application of medical infrared imaging, ... AAT Member Certification Qualification Courses for Technicians, respectively. , For the first time ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture ... choosing the right method is paramount to success. Selecting an inappropriate measurement method ... where multiple persons use the same equipment. Rare or expensive substances are wasted ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Old School Labs™, ... added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ... a bodybuilder in 2012 and in less than a year was able to turn ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: ... from an early age. “Life Under Blankets” is the creation of published author, Kimberly ... Circle Campus in Chicago. She went on to pursue a master’s degree in education ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... SAN DIEGO , Jan. 20, 2017 ResMed (NYSE: ... and 3B Medical ( Winter Haven, Florida ) today ... between the parties. BMC and 3B will be permitted to sell ... ResMed will make a one-time settlement payment to 3B to close ... The settlement did not include an admission of liability or wrongdoing ...
(Date:1/21/2017)... Jan. 20, 2017  Faruqi & Faruqi, LLP, a leading ... or the "Company") (NASDAQ: KMPH ) of the ... certain officers and directors and underwriters of the Company,s April ... role of lead plaintiff. The lawsuit has been ... for Johnson County on behalf of ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: